- Poster presentation
- Open Access
- Published:
Variant CAPS in an adult- the use of genetics
Pediatric Rheumatology volume 13, Article number: P27 (2015)
Introduction
Cryopyrin-associated periodic syndrome (CAPS) includes three overlapping disorders: familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and neonatal onset multisystem inflammatory disorder (NOMID). Once considerate separate entities, these hereditary autoinflammatory disorders have been found to share a common genetic basis, pathogenesis and treatment and are therefore now considered a continuous clinical spectrum of a single entity. CAPS is caused by dominantly inherited or de novo NRLP3 mutations
Objectives
The use of genetic methods for detecting somatic NLRP3 mosaicism in adult onset CAPS phenotype
Patients & methods
A 53 year old male, Christian Arab from North Israel, suffered for 2 years from an unclassified multi-system inflammatory disorder. Its chief features were weight loss, fever, maculopapular skin eruption, arthritis, lymph node enlargement, hepatosplenomegaly, bone periosteal reaction, all associated with a major acute phase response. The arthritis was chronic, with disease flares lasting weeks to months. He responded moderately well to high dose corticosteroids but not to immunosuppressive agents including DMARDs, anti TNF agents, rituximab, nor tocilizumab. Subsequently, he developed a moto-sensory peripheral neuropathy of the legs and sensorineural deafness. There was no evidence of amyloidosis nor a relevant family history.
Results
No mutations in MEFV, nor for TRAPS and MVK were found.
A variant in NRLP3 Tyr 570 Cys (Y750C) was found in peripheral blood cells and buccal mucosa.
The patient was treated with anti-IL-1 drugs. Anakinra was poorly tolerated and then switched to canakinumab 300 mg / 4 weeks sc with complete remission of all symptoms except for the sensorineural deafness and peripheral neuropathy.
Conclusion
The detection of somatic mosaicism can have major clinical implications for patients including access to efficacious treatment duly recognized by regulators, and more availability of needed frequent monitoring. Taking into account the patient's excellent response to IL -1 blockade, it is reasonable to hypothesize that its earlier institution might have prevented the appearance of the severe complications of deafness and neuropathy.
Author information
Authors and Affiliations
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Rozenbam, M., Rimar, D., Kaly, L. et al. Variant CAPS in an adult- the use of genetics. Pediatr Rheumatol 13 (Suppl 1), P27 (2015). https://doi.org/10.1186/1546-0096-13-S1-P27
Published:
DOI: https://doi.org/10.1186/1546-0096-13-S1-P27
Keywords
- Amyloidosis
- Tocilizumab
- Anakinra
- Canakinumab
- Sensorineural Deafness